| Methods | Phase 4, randomised, parallel‐design, open‐label safety trial 2 treatment arms: TPM and ZNS |
| Participants | Participants > 13 years with at least 2 seizures and 1 in the 3 months prior to screening and no AEDs in the previous 4 months Estimated number enrolled = 140 |
| Interventions | Monotherapy with TPM or ZNS Initial doses: TPM = 25 mg/d, ZNS = 100 mg/d. Maximum doses: TPM = 400 mg/d, ZNS = 600 mg/d |
| Outcomes | Cognitive function (change from baseline at 24 weeks) |
| Notes | Trial registered as NCT00154076 on ClincalTrials.gov and listed as completed but no results published. Trial sponsored by Eisai Korea, inquiries regarding this trial made to the sponsor but no data could be provided. If more information on this trial can be found, this trial will be included in future updates of the review. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.